Navigation Links
Zargis Medical Strikes Gold at 2010 Edison Awards

STAMFORD, Conn., May 14 /PRNewswire/ -- Zargis Medical Corp., a majority-owned subsidiary of Speedus Corp. (Nasdaq: SPDE), today announced that its Zargis Cardioscan device and the compatible 3M™ Littmann® Electronic Stethoscope Model 3200 were the joint recipients of a Gold Award on April 29th at The Edison Best New Products Award gala, presented by Discovery Channel in New York City. The prestigious Gold Award is the top honor given by the Edison Award Steering Committee for product excellence in innovation, creativity and ingenuity, as demonstrated by inventor Thomas Alva Edison. Zargis and 3M were recognized in the Electronics and Computers category—the category in which the Apple® iPhone was the 2009 Gold Award winner.

Zargis Cardioscan software supports physicians in analyzing cardiac sounds for the identification and classification of suspected murmurs, which can be signs of heart disease, and allows healthcare professionals to record, visualize and transmit recordings made with a stethoscope. The software represents a breakthrough in computer-aided auscultation that has the potential to reduce unnecessary referrals.

"Pairing the Littmann Electronic Stethoscope Model 3200 with Zargis Cardioscan software is a huge advancement in changing the way clinicians listen to and interpret heart sounds," said Debra Rectenwald, president and general manager, 3M Infection Prevention Division.

About Zargis Medical Corp.

Zargis is a global medical device company focused on improving health outcomes and cost-effectiveness through diagnostic support software and innovation. Zargis is majority-owned by Speedus Corp. (Nasdaq: SPDE), and both 3M Company and Siemens Corporate Research, a division of Siemens AG (NYSE: SI), hold equity positions.

For additional information about Zargis or Speedus Corp., contact Peter Hodge at 888.773.3669 (ext. 23) or, or visit the following Web sites: and

Statements contained herein that are not historical facts, including but not limited to statements about the Company's product, corporate identity and focus, may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company, including, but not limited to, the continuing development of the Company's sales, marketing and support efforts.

SOURCE Speedus Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Speedus Engages Morgan Joseph to Evaluate Strategic Alternatives for Zargis Subsidiary
2. Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference
3. Zargis Cardioscan Cleared for Sale in Canada
4. Zargis Cardioscan(TM) Featured on The Early Show on CBS
5. Zargis Cardioscan The Intelligent Stethoscope Now Available on
6. Zargis Cardioscan Jointly Named as Finalist in 2010 Edison Best New Product Awards
7. Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
10. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
11. Globus Medical Raises $110 Million in Series E Financing Round
Post Your Comments:
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... nouvelle approche consistant à combiner l,immunothérapie au traitement ...    --> Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... November 27, 2015 Ein ... fortgeschrittenem Krebs.   --> Ein neuer ... Krebs.   --> Ein neuer ... Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November 2015 ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge ... imaging in the Waterloo region. Using the Ocean Platform, family physicians can now ... their electronic medical record (EMR) without the need for redundant patient entry or ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
Breaking Medicine News(10 mins):